In March 2025, The Lancet Respiratory Medicine published a phase 2 clinical study article on China's first DPP-1 inhibitor, HSK31858, led by Academician Nan-shan Zhong and Professor Wei-jie Guan from ...
Bronchiectasis is one of the most common highly heterogeneous chronic inflammatory airway diseases in China. It has a long course, heavy symptom burden, and is prone to recurrent acute exacerbations, ...
Merck & Co.’s drug indicated as a monotherapy and as an add-on to either metformin or TZDs. Merck & Co.’s Januvia™ (sitagliptin phosphate), which the company says is the first and only DPP-4 inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback